EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retraction: Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis

Frontiers in Pharmacology · 11.11.2026 · 17

DOI: 10.3389/fphar.2026.2052163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Retraction: Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2052163

Vancouver

Retraction: Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2052163

BibTeX
@article{euvimed2026,
  title = {Retraction: Correction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2052163}
}
Kostenlos starten →